Disability-adjusted life year

Last updated
Disability-adjusted life years lost per 100,000 inhabitants in 2004:
.mw-parser-output .div-col{margin-top:0.3em;column-width:30em}.mw-parser-output .div-col-small{font-size:90%}.mw-parser-output .div-col-rules{column-rule:1px solid #aaa}.mw-parser-output .div-col dl,.mw-parser-output .div-col ol,.mw-parser-output .div-col ul{margin-top:0}.mw-parser-output .div-col li,.mw-parser-output .div-col dd{page-break-inside:avoid;break-inside:avoid-column}
.mw-parser-output .legend{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .legend-color{display:inline-block;min-width:1.25em;height:1.25em;line-height:1.25;margin:1px 0;text-align:center;border:1px solid black;background-color:transparent;color:black}.mw-parser-output .legend-text{}
No data
Fewer than 9,250
9,250-16,000
16,000-22,750
22,750-29,500
29,500-36,250
36,250-43,000
43,000-49,750
49,750-56,500
56,500-63,250
63,250-70,000
70,000-80,000
More than 80,000 All Causes world map - DALY - WHO2004.svg
Disability-adjusted life years lost per 100,000 inhabitants in 2004:
  No data
  Fewer than 9,250
  9,250–16,000
  16,000–22,750
  22,750–29,500
  29,500–36,250
  36,250–43,000
  43,000–49,750
  49,750–56,500
  56,500–63,250
  63,250–70,000
  70,000–80,000
  More than 80,000

Disability-adjusted life years (DALYs) are a measure of overall disease burden, expressed as the number of years lost due to ill-health, disability, or early death. It was developed in the 1990s as a way of comparing the overall health and life expectancy of different countries.

Contents

DALYs have become more common in the field of public health and health impact assessment (HIA). They include not only the potential years of life lost due to premature death but also equivalent years of 'healthy' life lost by virtue of being in states of poor health or disability. In so doing, mortality and morbidity are combined into a single, common metric. [2]

Calculation

adjusted life year DALY disability affected life year infographic.svg
adjusted life year

Disability-adjusted life years are a societal measure of the disease or disability burden in populations. DALYs are calculated by combining measures of life expectancy as well as the adjusted quality of life during a burdensome disease or disability for a population. DALYs are related to the quality-adjusted life year (QALY) measure; however, QALYs only measure the benefit with and without medical intervention and therefore do not measure the total burden. Also, QALYs tend to be an individual measure and not a societal measure.

Traditionally, health liabilities were expressed using one measure, the years of life lost (YLL) due to dying early. A medical condition that did not result in dying younger than expected was not counted. The burden of living with a disease or disability is measured by the years lost due to disability (YLD) component, sometimes also known as years lost due to disease or years lived with disability/disease. [2]

DALYs are calculated by taking the sum of these two components: [3]

DALY = YLL + YLD

The DALY relies on an acceptance that the most appropriate measure of the effects of chronic illness is time, both time lost due to premature death and time spent disabled by disease. One DALY, therefore, is equal to one year of healthy life lost.

How much a medical condition affects a person is called the disability weight (DW). This is determined by disease or disability and does not vary with age. Tables have been created of thousands of diseases and disabilities, ranging from Alzheimer's disease to loss of finger, with the disability weight meant to indicate the level of disability that results from the specific condition.

Examples of disability weight
ConditionDW 2004 [4] DW 2010 [5]
Alzheimer's and other dementias0.6660.666
Blindness0.5940.195
Schizophrenia0.5280.576
AIDS, not on ART 0.5050.547
Burns 20%–60% of body0.4410.438
Fractured femur0.3720.308
Moderate depression episode0.3500.406
Amputation of foot0.3000.021–0.1674
Deafness0.2290.167–0.281
Infertility0.1800.026–0.056
Amputation of finger0.1020.030
Lower back pain0.0610.0322–0.0374

Examples of the disability weight are shown on the right. Some of these are "short term", and the long-term weights may be different.

The most noticeable change between the 2004 and 2010 figures for disability weights above are for blindness as it was considered the weights are a measure of health rather than well-being (or welfare) and a blind person is not considered to be ill. "In the GBD terminology, the term disability is used broadly to refer to departures from optimal health in any of the important domains of health." [6]

At the population level, the disease burden as measured by DALYs is calculated by adding YLL to YLD. YLL uses the life expectancy at the time of death. [7] YLD is determined by the number of years disabled weighted by level of disability caused by a disability or disease using the formula:

YLD = I × DW × L

In this formula, I = number of incident cases in the population, DW = disability weight of specific condition, and L = average duration of the case until remission or death (years). There is also a prevalence (as opposed to incidence) based calculation for YLD. Number of years lost due to premature death is calculated by

YLL = N × L

where N = number of deaths due to condition, L = standard life expectancy at age of death. [2] Life expectancies are not the same at different ages. For example, in Paleolithic era, life expectancy at birth was 33 years, but life expectancy at the age of 15 was an additional 39 years (total 54). [8]

Historically Japanese life expectancy statistics have been used as the standard for measuring premature death, as the Japanese have the longest life expectancies. [9] Other approaches have since emerged, include using national life tables for YLL calculations, or using the reference life table derived by the GBD study. [10] [11]

Age weighting

Some studies use DALYs calculated to place greater value on a year lived as a young adult. This formula produces average values around age 10 and age 55, a peak around age 25, and lowest values among very young children and very old people. Disability Adjusted Life Year Weight Plot.svg
Some studies use DALYs calculated to place greater value on a year lived as a young adult. This formula produces average values around age 10 and age 55, a peak around age 25, and lowest values among very young children and very old people.

The World Health Organization (WHO) used age weighting and time discounting at 3 percent in DALYs prior to 2010 but discontinued using them starting in 2010. [13]

There are two components to this differential accounting of time: age-weighting and time-discounting. Age-weighting is based on the theory of human capital. Commonly, years lived as a young adult are valued more highly than years spent as a young child or older adult, as these are years of peak productivity. Age-weighting receives considerable criticism for valuing young adults at the expense of children and the old. Some criticize, while others rationalize, this as reflecting society's interest in productivity and receiving a return on its investment in raising children. This age-weighting system means that somebody disabled at 30 years of age, for ten years, would be measured as having a higher loss of DALYs (a greater burden of disease), than somebody disabled by the same disease or injury at the age of 70 for ten years.

This age-weighting function is by no means a universal methodology in HALY studies, but is common when using DALYs. Cost-effectiveness studies using QALYs, for example, do not discount time at different ages differently. [14] This age-weighting function applies only to the calculation of DALYs lost due to disability. Years lost to premature death are determined from the age at death and life expectancy.

The Global Burden of Disease Study (GBD) 2001–2002 counted disability adjusted life years equally for all ages, but the GBD 1990 and GBD 2004 studies used the formula [15]

[16] where is the age at which the year is lived and is the value assigned to it relative to an average value of 1.

In these studies, future years were also discounted at a 3% rate to account for future health care losses. Time discounting, which is separate from the age-weighting function, describes preferences in time as used in economic models. [17]

The effects of the interplay between life expectancy and years lost, discounting, and social weighting are complex, depending on the severity and duration of illness. For example, the parameters used in the GBD 1990 study generally give greater weight to deaths at any year prior to age 39 than afterward, with the death of a newborn weighted at 33 DALYs and the death of someone aged 5–20 weighted at approximately 36 DALYs. [18]

As a result of numerous discussions, by 2010 the World Health Organization had abandoned the ideas of age weighting and time discounting. [13] They had also substituted the idea of prevalence for incidence (when a condition started) because this is what surveys measure.

Economic applications

The methodology is not an economic measure. It measures how much healthy life is lost. It does not assign a monetary value to any person or condition, and it does not measure how much productive work or money is lost as a result of death and disease. However, HALYs, including DALYs and QALYs, are especially useful in guiding the allocation of health resources as they provide a common numerator, allowing for the expression of utility in terms of dollar/DALY, or dollar/QALY. [14] For example, in Gambia, provision of the pneumococcal conjugate vaccine costs $670 per DALY saved. [19] This number can then be compared to other treatments for other diseases, to determine whether investing resources in preventing or treating a different disease would be more efficient in terms of overall health.

Examples

Schizophrenia has a 0.53 weighting and a broken femur a 0.37 weighting in the latest WHO weightings. [4]

Australia

Cancer (25.1/1,000), cardiovascular (23.8/1,000), mental problems (17.6/1,000), neurological (15.7/1,000), chronic respiratory (9.4/1,000) and diabetes (7.2/1,000) are the main causes of good years of expected life lost to disease or premature death. [20] Despite this, Australia has one of the longest life expectancies in the world.

Africa

These illustrate the problematic diseases and outbreaks occurring in 2013 in Zimbabwe, shown to have the greatest impact on health disability were typhoid, anthrax, malaria, common diarrhea, and dysentery. [21]

PTSD rates

Posttraumatic stress disorder (PTSD) DALY estimates from 2004 for the world's 25 most populous countries give Asian/Pacific countries and the United States as the places where PTSD impact is most concentrated (as shown here).

Noise-induced hearing loss

The disability-adjusted life years attributable to hearing impairment for noise-exposed U.S. workers across all industries was calculated to be 2.53 healthy years lost annually per 1,000 noise-exposed workers. Workers in the mining and construction sectors lost 3.45 and 3.09 healthy years per 1,000 workers, respectively. Overall, 66% of the sample worked in the manufacturing sector and represented 70% of healthy years lost by all workers. [22]

History and usage

Originally developed by Harvard University for the World Bank in 1990, the World Health Organization subsequently adopted the method in 1996 as part of the Ad hoc Committee on Health Research "Investing in Health Research & Development" report. The DALY was first conceptualized by Christopher J. L. Murray and Lopez in work carried out with the World Health Organization and the World Bank known as the Global Burden of Disease Study, which was undertaken in 1990. [23] It is now a key measure employed by the United Nations World Health Organization in such publications as its Global Burden of Disease. [24]

The DALY was also used in the 1993 World Development Report. [25] :x

Criticism

Both DALYs and QALYs are forms of HALYs, health-adjusted life years.

Some critics have alleged that DALYs are essentially an economic measure of human productive capacity for the affected individual. [26] [ irrelevant citation ] In response, defenders of DALYs have argued that while DALYs have an age-weighting function that has been rationalized based on the economic productivity of persons at that age, health-related quality of life measures are used to determine the disability weights, which range from 0 to 1 (no disability to 100% disabled) for all disease. These defenders emphasize that disability weights are based not on a person's ability to work, but rather on the effects of the disability on the person's life in general. Hence, mental illness is one of the leading diseases as measured by global burden of disease studies, with depression accounting for 51.84 million DALYs. Perinatal conditions, which affect infants with a very low age-weight function, are the leading cause of lost DALYs at 90.48 million. Measles is fifteenth at 23.11 million. [14] [27] [28]

Some commentators have expressed doubt over whether the disease burden surveys (such as EQ-5D) fully capture the impacts of mental illness, due to factors including ceiling effects. [29] [30] [31]

According to Pliskin et al., the QALY model requires utility independent, risk neutral, and constant proportional tradeoff behaviour. [32] Because of these theoretical assumptions, the meaning and usefulness of the QALY is debated. [33] [34] Perfect health is difficult, if not impossible, to define. Some argue that there are health states worse than being dead, and that therefore there should be negative values possible on the health spectrum (indeed, some health economists have incorporated negative values into calculations). Determining the level of health depends on measures that some argue place disproportionate importance on physical pain or disability over mental health. [35]

The method of ranking interventions on grounds of their cost per QALY gained ratio (or ICER) is controversial because it implies a quasi-utilitarian calculus to determine who will or will not receive treatment. [36] However, its supporters argue that since health care resources are inevitably limited, this method enables them to be allocated in the way that is approximately optimal for society, including most patients. Another concern is that it does not take into account equity issues such as the overall distribution of health states – particularly since younger, healthier cohorts have many times more QALYs than older or sicker individuals. As a result, QALY analysis may undervalue treatments which benefit the elderly or others with a lower life expectancy. Also, many would argue that all else being equal, patients with more severe illness should be prioritised over patients with less severe illness if both would get the same absolute increase in utility. [37]

As early as 1989, Loomes and McKenzie recommended that research be conducted concerning the validity of QALYs. [38] In 2010, with funding from the European Commission, the European Consortium in Healthcare Outcomes and Cost-Benefit Research (ECHOUTCOME) began a major study on QALYs as used in health technology assessment. [39] Ariel Beresniak, the study's lead author, was quoted as saying that it was the "largest-ever study specifically dedicated to testing the assumptions of the QALY". [40] In January 2013, at its final conference, ECHOUTCOME released preliminary results of its study which surveyed 1361 people "from academia" in Belgium, France, Italy and the UK. [40] [41] [42] The researchers asked the subjects to respond to 14 questions concerning their preferences for various health states and durations of those states (e.g., 15 years limping versus 5 years in a wheelchair). [42] They concluded that "preferences expressed by the respondents were not consistent with the QALY theoretical assumptions" that quality of life can be measured in consistent intervals, that life-years and quality of life are independent of each other, that people are neutral about risk, and that willingness to gain or lose life-years is constant over time. [42] ECHOUTCOME also released "European Guidelines for Cost-Effectiveness Assessments of Health Technologies", which recommended not using QALYs in healthcare decision making. [43] Instead, the guidelines recommended that cost-effectiveness analyses focus on "costs per relevant clinical outcome". [40] [43]

In response to the ECHOUTCOME study, representatives of the National Institute for Health and Care Excellence, the Scottish Medicines Consortium, and the Organisation for Economic Co-operation and Development made the following points. First, QALYs are better than alternative measures. [40] [41] Second, the study was "limited". [40] [41] Third, problems with QALYs were already widely acknowledged. [41] Fourth, the researchers did not take budgetary constraints into consideration. [41] Fifth, the UK's National Institute for Health and Care Excellence uses QALYs that are based on 3395 interviews with residents of the UK, as opposed to residents of several European countries. [40] Finally, people who call for the elimination of QALYs may have "vested interests". [40]

See also

Related Research Articles

<span class="mw-page-title-main">Preventive healthcare</span> Prevention of the occurrence of diseases

Preventive healthcare, or prophylaxis, is the application of healthcare measures to prevent diseases. Disease and disability are affected by environmental factors, genetic predisposition, disease agents, and lifestyle choices, and are dynamic processes that begin before individuals realize they are affected. Disease prevention relies on anticipatory actions that can be categorized as primal, primary, secondary, and tertiary prevention.

<span class="mw-page-title-main">Quality-adjusted life year</span> Measure of disease burden

The quality-adjusted life year (QALY) is a generic measure of disease burden, including both the quality and the quantity of life lived. It is used in economic evaluation to assess the value of medical interventions. One QALY equates to one year in perfect health. QALY scores range from 1 to 0 (dead). QALYs can be used to inform health insurance coverage determinations, treatment decisions, to evaluate programs, and to set priorities for future programs.

<span class="mw-page-title-main">Global health</span> Health of populations in a global context

Global health is the health of the populations in the worldwide context; it has been defined as "the area of study, research, and practice that places a priority on improving health and achieving equity in health for all people worldwide". Problems that transcend national borders or have a global political and economic impact are often emphasized. Thus, global health is about worldwide health improvement, reduction of disparities, and protection against global threats that disregard national borders, including the most common causes of human death and years of life lost from a global perspective.

<span class="mw-page-title-main">Health in India</span> Overview of health in India

India's population in 2021 as per World Bank is 1.39 billion. Being the world's most populous country and one of its fastest-growing economies, India experiences both challenges and opportunities in context of public health. India is a hub for pharmaceutical and biotechnology industries; world-class scientists, clinical trials and hospitals yet country faces daunting public health challenges like child undernutrition, high rates of neonatal and maternal mortality, growth in noncommunicable diseases, high rates of road traffic accidents and other health related issues.

In epidemiology and demography, age adjustment, also called age standardization, is a technique used to allow statistical populations to be compared when the age profiles of the populations are quite different.

The Global Burden of Disease Study (GBD) is a comprehensive regional and global research program of disease burden that assesses mortality and disability from major diseases, injuries, and risk factors. GBD is a collaboration of over 3600 researchers from 145 countries. Under principal investigator Christopher J.L. Murray, GBD is based in the Institute for Health Metrics and Evaluation (IHME) at the University of Washington and funded by the Bill and Melinda Gates Foundation.

<span class="mw-page-title-main">Disease burden</span> Impact of diseases

Disease burden is the impact of a health problem as measured by financial cost, mortality, morbidity, or other indicators. It is often quantified in terms of quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs). Both of these metrics quantify the number of years lost due to disability (YLDs), sometimes also known as years lost due to disease or years lived with disability/disease. One DALY can be thought of as one year of healthy life lost, and the overall disease burden can be thought of as a measure of the gap between current health status and the ideal health status. According to an article published in The Lancet in June 2015, low back pain and major depressive disorder were among the top ten causes of YLDs and were the cause of more health loss than diabetes, chronic obstructive pulmonary disease, and asthma combined. The study based on data from 188 countries, considered to be the largest and most detailed analysis to quantify levels, patterns, and trends in ill health and disability, concluded that "the proportion of disability-adjusted life years due to YLDs increased globally from 21.1% in 1990 to 31.2% in 2013." The environmental burden of disease is defined as the number of DALYs that can be attributed to environmental factors. Similarly, the work-related burden of disease is defined as the number of deaths and DALYs that can be attributed to occupational risk factors to human health. These measures allow for comparison of disease burdens, and have also been used to forecast the possible impacts of health interventions. By 2014, DALYs per head were "40% higher in low-income and middle-income regions."

Years of potential life lost (YPLL) or potential years of life lost (PYLL) is an estimate of the average years a person would have lived if they had not died prematurely. It is, therefore, a measure of premature mortality. As an alternative to death rates, it is a method that gives more weight to deaths that occur among younger people. An alternative is to consider the effects of both disability and premature death using disability adjusted life years.

Australia is a high income country, and this is reflected in the good status of health of the population overall. In 2011, Australia ranked 2nd on the United Nations Development Programme's Human Development Index, indicating the level of development of a country. Despite the overall good status of health, the disparities occurring in the Australian healthcare system are a problem. The poor and those living in remote areas as well as indigenous people are, in general, less healthy than others in the population, and programs have been implemented to decrease this gap. These include increased outreach to the indigenous communities and government subsidies to provide services for people in remote or rural areas.

Health care services in Nepal are provided by both public and private sectors and are generally regarded as failing to meet international standards. Prevalence of disease is significantly higher in Nepal than in other South Asian countries, especially in rural areas. Moreover, the country's topographical and sociological diversity results in periodic epidemics of infectious diseases, epizootics and natural hazards such as floods, forest fires, landslides, and earthquakes. But, recent surge in Non communicable diseases has emerged as the main public health concern and this accounts for more than two-thirds of total mortality in country. A large section of the population, particularly those living in rural poverty, are at risk of infection and mortality by communicable diseases, malnutrition and other health-related events. Nevertheless, some improvements in health care can be witnessed; most notably, there has been significant improvement in the field of maternal health. These improvements include:

<span class="mw-page-title-main">Health in Tajikistan</span> Overview of health in Tajikistan

The Tajikistan health system is influenced by the former Soviet legacy. It is ranked as the poorest country within the WHO European region, including the lowest total health expenditure per capita. Tajikistan is ranked 129th as Human Development Index of 188 countries, with an Index of 0.627 in 2016. In 2016, the SDG Index value was 56. In Tajikistan health indicators such as infant and maternal mortality rates are among the highest of the former Soviet republics. In the post-Soviet era, life expectancy has decreased because of poor nutrition, polluted water supplies, and increased incidence of cholera, malaria, tuberculosis, and typhoid. Because the health care system has deteriorated badly and receives insufficient funding and because sanitation and water supply systems are in declining condition, Tajikistan has a high risk of epidemic disease.

According to the World Bank income level classification, Portugal is considered to be a high income country. Its population was of 10,283,822 people, by 1 July 2019. WHO estimates that 21.7% of the population is 65 or more years of age (2018), a proportion that is higher than the estimates for the WHO European Region.

<span class="mw-page-title-main">Christopher J. L. Murray</span> American academic and director of the IHME

Christopher Murray is an American physician, health economist, and global health researcher. He is a professor at the University of Washington in Seattle, where he is Chair of Health Metrics Science and the director of the Institute for Health Metrics and Evaluation (IHME).

<span class="mw-page-title-main">Institute for Health Metrics and Evaluation</span> Statistics institute for public health under the University of Washington, based in Seattle

The Institute for Health Metrics and Evaluation (IHME) is a research institute working in the area of global health statistics and impact evaluation at the University of Washington in Seattle. The Institute is headed by Christopher J.L. Murray, a physician and health economist, and professor at the University of Washington Department of Global Health, which is part of the School of Medicine. IHME conducts research and trains scientists, policymakers, and the public in health metrics concepts, methods, and tools. Its mission includes judging the effectiveness and efficacy of health initiatives and national health systems. IHME also trains students at the post-baccalaureate and post-graduate levels.

<span class="mw-page-title-main">Health in Brunei</span>

Brunei's healthcare system is managed by the Brunei Ministry of Health and funded by the General Treasury. It consists of around 15 health centers, ten clinics and 22 maternal facilities, considered to be of reasonable standard. There are also two private hospitals. Cardiovascular disease, cancer, and diabetes are the leading cause of death in the country, with life expectancy around 75 years, a vast improvement from 1961. Brunei's human development index (HCI) improved from 0.81 in 2002 to 0.83 in 2021, expanding at an average annual rate of 0.14%. According to the UN's Human Development Report 2020, the HCI for girls in the country is greater than for boys, though aren't enough statistics in Brunei to break down HCI by socioeconomic classes. Brunei is the second country in Southeast Asia after Singapore to be rated 47th out of 189 nations on the UN HDI 2019 and has maintained its position in the Very High Human Development category. Being a culturally taboo subject, the rate of suicide has not been investigated.

<span class="mw-page-title-main">Health in Norway</span> Overview of health in Norway

Health in Norway, with its early history of poverty and infectious diseases along with famines and epidemics, was poor for most of the population at least into the 1800s. The country eventually changed from a peasant society to an industrial one and established a public health system in 1860. Due to the high life expectancy at birth, the low under five mortality rate and the fertility rate in Norway, it is fair to say that the overall health status in the country is generally good.

Environmental risk transition is the process by which traditional communities with associated environmental health issues become more economically developed and experience new health issues. In traditional or economically undeveloped regions, humans often suffer and die from infectious diseases or of malnutrition due to poor food, water, and air quality. As economic development occurs, these environmental issues are reduced or solved, and others begin to arise. There is a shift in the character of these environmental changes, and as a result, a shift in causes of death and disease.

<span class="mw-page-title-main">Diabetes in India</span>

India has an estimated 77 million people formally diagnosed with diabetes, which makes it the second most affected in the world, after China. Furthermore, 700,000 Indians died of diabetes, hyperglycemia, kidney disease or other complications of diabetes in 2020. One in six people (17%) in the world with diabetes is from India. The number is projected to grow by 2045 to become 134 million per the International Diabetes Federation.

The life-years lost or years of lost life (YLL) is a unit to measure the number of expected years of human life lost following an unexpected event, such as death by illness, crime or war.

References

  1. "Disease and injury country estimates". World Health Organization. Archived from the original on 2009-11-11. Retrieved Nov 11, 2009.
  2. 1 2 3 "Metrics: Disability-Adjusted Life Year (DALY)". WHO. Archived from the original on Feb 20, 2020. Retrieved 2020-01-02.
  3. Havelaar, Arie (August 2007). "Methodological choices for calculating the disease burden and cost-of-illness of foodborne zoonoses in European countries" (PDF). Med-Vet-Net. Archived from the original (PDF) on 21 January 2009. Retrieved 2008-04-05.
  4. 1 2 "Global burden of disease 2004 update: disability weights for diseases and conditions" (PDF). Archived (PDF) from the original on 2016-11-30. Retrieved 2016-07-25.
  5. WHO 2013.
  6. WHO 2013, p. 15.
  7. Martinez, Ramon; Soliz, Patricia; Caixeta, Roberta; Ordunez, Pedro (9 January 2019). "Reflection on modern methods: years of life lost due to premature mortality—a versatile and comprehensive measure for monitoring non-communicable disease mortality". International Journal of Epidemiology. 48 (4): 1367–1376. doi: 10.1093/ije/dyy254 . PMC   6693813 . PMID   30629192.
  8. Kaplan, Hillard; Hill, Kim; Lancaster, Jane; Hurtado, A. Magdalena (2000). "A theory of human life history evolution: Diet, intelligence, and longevity". Evolutionary Anthropology: Issues, News, and Reviews. 9 (4): 156–185. doi:10.1002/1520-6505(2000)9:4<156::AID-EVAN5>3.0.CO;2-7. S2CID   2363289.
  9. Menken M, Munsat TL, Toole JF (March 2000). "The global burden of disease study: implications for neurology". Arch. Neurol. 57 (3): 418–20. CiteSeerX   10.1.1.660.4176 . doi:10.1001/archneur.57.3.418. PMID   10714674.
  10. Devleesschauwer B, McDonald SA, Speybroeck N, Wyper GM (2020). "Valuing the years of life lost due to COVID-19: the differences and pitfalls". International Journal of Public Health. 65 (6): 719–720. doi: 10.1007/s00038-020-01430-2 . PMC   7370635 . PMID   32691080.
  11. Wyper GM, Devleesschauwer B, Mathers CD, McDonald SA, Speybroeck N (2022). "Years of life lost methods must remain fully equitable and accountable". European Journal of Epidemiology. 37 (2): 215–216. doi: 10.1007/s10654-022-00846-9 . PMC   8894819 . PMID   35244840.
  12. Murray, Christopher J (1994). "Quantifying the burden of disease: the technical basis for disability-adjusted life years". Bulletin of the World Health Organization. 72 (3): 429–45. PMC   2486718 . PMID   8062401.
  13. 1 2 "WHO methods and data sources for global burden of disease estimates 2000–2011" (PDF). World Health Organization. 2013. Archived (PDF) from the original on 2016-09-09. Retrieved Jul 27, 2016.
  14. 1 2 3 Gold, MR; Stevenson, D; Fryback, DG (2002). "HALYS and QALYS and DALYS, oh my: similarities and differences in summary measures of population health". Annual Review of Public Health. 23: 115–34. doi:10.1146/annurev.publhealth.23.100901.140513. PMID   11910057.
  15. "WHO | Disability weights, discounting and age weighting of DALYs". WHO. Archived from the original on September 26, 2013. Retrieved 2020-01-02.
  16. Prüss-Üstün, A.; Mathers, C.; Corvalán, C.; Woodward, A. (2003). "3 The Global Burden of Disease concept". Introduction and methods: Assessing the environmental burden of disease at national and local levels. Vol. 1. World Health Organization. ISBN   978-9241546201. Archived from the original (PDF) on 2014-02-01.
  17. Kramer, Alexander; Hossain, Mobarak; Kraas, Frauke (2011). Health in megacities and urban areas. Heidelberg: Physica-Verlag. ISBN   978-3-7908-2732-3.
  18. Mathers CD, Ezzati M, Lopez AD (2007). "Measuring the burden of neglected tropical diseases: the global burden of disease framework". PLOS Negl Trop Dis. 1 (2): e114. doi: 10.1371/journal.pntd.0000114 . PMC   2100367 . PMID   18060077. Open Access logo PLoS transparent.svg
  19. Kim, SY; Lee, G; Goldie, SJ (Sep 3, 2010). "Economic evaluation of pneumococcal conjugate vaccination in The Gambia". BMC Infectious Diseases. 10: 260. doi: 10.1186/1471-2334-10-260 . PMC   2944347 . PMID   20815900. Open Access logo PLoS transparent.svg
  20. Chant, Kerry (November 2008). "The Health of the People of New South Wales (summary report)" (PDF). Chief Health Officer, Government of New South Wales. Archived from the original (PDF) on 2009-01-21. Retrieved 2009-01-17.{{cite journal}}: Cite journal requires |journal= (help)
  21. Zimbabwe, Ministry of Health and Child Welfare (December 2013). "Zimbabwe Weekly Epidemiological Bulletin" (PDF). World Health Organization, Government of Zimbabwe. Archived (PDF) from the original on 2014-02-28. Retrieved 2014-02-24.{{cite journal}}: Cite journal requires |journal= (help)
  22. Masterson, EA; Bushnell, PT; Themann, CL; Morata, TC (2016). "Hearing Impairment Among Noise-Exposed Workers — United States, 2003–2012". MMWR Morb Mortal Wkly Rep. 65 (15): 389–394. doi: 10.15585/mmwr.mm6515a2 . PMID   27101435.
  23. Murray, C. J.; Lopez, A. D.; Jamison, D. T. (1994). "The global burden of disease in 1990: summary results, sensitivity analysis and future directions". Bulletin of the World Health Organization. 72 (3): 495–509. ISSN   0042-9686. PMC   2486716 . PMID   8062404.
  24. "Global Health Estimates". World Health Organization. Archived from the original on 2015-08-31.
  25. World Bank (1993). World Development Report 1993: Investing in Health. Oxford University Press. doi:10.1596/0-1952-0890-0. ISBN   978-0-19-520890-0. Archived from the original on 2016-11-27.
  26. Thacker SB, Stroup DF, Carande-Kulis V, Marks JS, Roy K, Gerberding JL (2006). "Measuring the public's health". Public Health Rep. 121 (1): 14–22. doi:10.1177/003335490612100107. PMC   1497799 . PMID   16416694.
  27. Kramer, Alexander, Md. Mobarak Hossain Khan, Frauke Kraas (2011). Health in megacities and urban areas. Heidelberg: Physica-Verlag. ISBN   978-3-7908-2732-3.{{cite book}}: CS1 maint: multiple names: authors list (link)
  28. Murray CJ (1994). "Quantifying the burden of disease: the technical basis for disability-adjusted life years". Bull World Health Organ. 72 (3): 429–445. PMC   2486718 . PMID   8062401.
  29. Papaioannou, Diana; Brazier, John; Parry, Glenys (1 September 2011). "How Valid and Responsive Are Generic Health Status Measures, such as EQ-5D and SF-36, in Schizophrenia? A Systematic Review". Value in Health. 14 (6): 907–920. doi:10.1016/j.jval.2011.04.006. PMC   3179985 . PMID   21914513 . Retrieved 4 May 2018.
  30. Brazier, John (2010). "Is the EQ–5D fit for purpose in mental health?" (PDF). The British Journal of Psychiatry. 197 (5): 348–349. doi:10.1192/bjp.bp.110.082453. PMID   21037210. S2CID   902903. Archived (PDF) from the original on 2016-01-08.
  31. Saarni, Samuli I.; Viertiö, Satu; Perälä, Jonna; Koskinen, Seppo; Lönnqvist, Jouko; Suvisaari, Jaana (2010). "Quality of life of people with schizophrenia, bipolar disorder and other psychotic disorders". The British Journal of Psychiatry. 197 (5): 386–394. doi: 10.1192/bjp.bp.109.076489 . PMID   21037216. S2CID   4676470. Archived from the original on 2016-01-29.
  32. Pliskin, J. S.; Shepard, D. S.; Weinstein, M. C. (1980). "Utility Functions for Life Years and Health Status". Operations Research. 28 (1): 206–24. doi:10.1287/opre.28.1.206. JSTOR   172147.
  33. Prieto, Luis; Sacristán, José A (2003). "Problems and solutions in calculating quality-adjusted life years (QALYs)". Health and Quality of Life Outcomes. 1: 80. doi: 10.1186/1477-7525-1-80 . PMC   317370 . PMID   14687421. Open Access logo PLoS transparent.svg
  34. Mortimer, D.; Segal, L. (2007). "Comparing the Incomparable? A Systematic Review of Competing Techniques for Converting Descriptive Measures of Health Status into QALY-Weights". Medical Decision Making. 28 (1): 66–89. doi:10.1177/0272989X07309642. PMID   18263562. S2CID   40830765.
  35. Dolan, P. (January 2008). "Developing methods that really do value the 'Q' in the QALY" (PDF). Health Economics, Policy and Law. 3 (1): 69–77. doi:10.1017/S1744133107004355. PMID   18634633. S2CID   25353890. Archived from the original (PDF) on 2016-08-03. Retrieved 2018-08-31.
  36. Schlander, Michael (2010-05-23), Measures of efficiency in healthcare: QALMs about QALYs? (PDF), Institute for Innovation & Valuation in Health Care, archived from the original (PDF) on 2011-07-14, retrieved 2010-05-23
  37. Nord, Erik; Pinto, Jose Luis; Richardson, Jeff; Menzel, Paul; Ubel, Peter (1999). "Incorporating societal concerns for fairness in numerical valuations of health programmes". Health Economics. 8 (1): 25–39. doi:10.1002/(SICI)1099-1050(199902)8:1<25::AID-HEC398>3.0.CO;2-H. PMID   10082141.
  38. Loomes, Graham; McKenzie, Lynda (1989). "The use of QALYs in health care decision making". Social Science & Medicine. 28 (4): 299–308. doi:10.1016/0277-9536(89)90030-0. ISSN   0277-9536. PMID   2649989.
  39. "ECHOUTCOME: European Consortium in Healthcare Outcomes and Cost-Benefit Research". Archived from the original on 2016-10-08.
  40. 1 2 3 4 5 6 7 Holmes, David (March 2013). "Report triggers quibbles over QALYs, a staple of health metrics". Nature Medicine. 19 (3): 248. doi: 10.1038/nm0313-248 . PMID   23467219.
  41. 1 2 3 4 5 Dreaper, Jane (24 January 2013). "Researchers claim NHS drug decisions 'are flawed'". BBC News. Retrieved 2017-05-30.
  42. 1 2 3 Beresniak, Ariel; Medina-Lara, Antonieta; Auray, Jean Paul; De Wever, Alain; Praet, Jean-Claude; Tarricone, Rosanna; Torbica, Aleksandra; Dupont, Danielle; Lamure, Michel; Duru, Gerard (2015). "Validation of the Underlying Assumptions of the Quality-Adjusted Life-Years Outcome: Results from the ECHOUTCOME European Project". PharmacoEconomics. 33 (1): 61–69. doi:10.1007/s40273-014-0216-0. ISSN   1170-7690. PMID   25230587. S2CID   5392762.
  43. 1 2 European Consortium in Healthcare Outcomes and Cost-Benefit Research (ECHOUTCOME). "European Guidelines for Cost-Effectiveness Assessments of Health Technologies" (PDF). Archived from the original (PDF) on 2015-08-14.